BlackRock Amends Passive Stake in Acadia Pharmaceuticals

Ticker: ACAD · Form: SC 13G/A · Filed: 2024-01-26T00:00:00.000Z

Sentiment: neutral

Topics: institutional-ownership, amendment, passive-investing

TL;DR

**BlackRock still holds ACADIA PHARMACEUTICALS stock, signaling institutional confidence.**

AI Summary

BlackRock Inc. filed an amended SC 13G/A on January 26, 2024, indicating its ownership of ACADIA PHARMACEUTICALS INC common stock as of December 31, 2023. This filing is an amendment (Amendment No: 2) to a previous filing, showing BlackRock's continued significant, but passive, stake in Acadia Pharmaceuticals. For investors, this matters because BlackRock is a major institutional investor, and its continued holding signals a degree of confidence in the company's long-term prospects, even if the exact percentage of ownership isn't detailed in this snippet.

Why It Matters

BlackRock's continued passive ownership in ACADIA PHARMACEUTICALS INC suggests institutional confidence, which can be a positive signal for current and prospective shareholders.

Risk Assessment

Risk Level: low — This filing is a routine update from a large institutional investor and does not indicate any immediate significant risk or change in company operations.

Analyst Insight

An investor should view this as a routine update from a major institutional holder, suggesting stability rather than an immediate catalyst for buying or selling. Further research into Acadia's fundamentals and BlackRock's overall investment strategy would be prudent.

Key Players & Entities

Forward-Looking Statements

FAQ

What type of filing is this document?

This document is an SC 13G/A, which is an amendment (Amendment No: 2) to a Schedule 13G filing under the Securities Exchange Act of 1934.

Who is the reporting person in this filing?

The reporting person is BlackRock, Inc., a large institutional investment manager.

What company's securities are being reported on in this filing?

The securities being reported on belong to ACADIA PHARMACEUTICALS INC, specifically their Common Stock.

What was the 'Date of Event Which Requires Filing of this Statement'?

The date of the event which requires filing of this statement was December 31, 2023.

Under which rule is this Schedule 13G/A filed?

This Schedule 13G/A is filed under Rule 13d-1(b) of the Securities Exchange Act of 1934, as indicated by the 'X' in the appropriate box.

From the Filing

EDGAR Filing Documents for 0001086364-24-004855 This page uses Javascript. Your browser either doesn't support Javascript or you have it turned off. To see this page as it is meant to appear please use a Javascript enabled browser. SEC.gov EDGAR Latest Filings Filings search tools Filing Detail SEC Home Company Search Current Page Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] SEC Accession No. 0001086364-24-004855 Filing Date 2024-01-26 Accepted 2024-01-26 17:25:22 Documents 1 Document Format Files Seq Description Document Type Size 1 us0042251084_012624.txt SC 13G/A 11890 Complete submission text file 0001086364-24-004855.txt 13725 Mailing Address 12830 EL CAMINO REAL SUITE 400 SAN DIEGO CA 92130 Business Address 12830 EL CAMINO REAL SUITE 400 SAN DIEGO CA 92130 858-558-2871 ACADIA PHARMACEUTICALS INC (Subject) CIK : 0001070494 (see all company filings) EIN. : 061376651 | State of Incorp.: DE | Fiscal Year End: 1231 Type: SC 13G/A | Act: 34 | File No.: 005-80011 | Film No.: 24569147 SIC : 2834 Pharmaceutical Preparations (CF Office: 03 Life Sciences) Mailing Address 50 HUDSON YARDS NEW YORK NY 10001 Business Address 50 HUDSON YARDS NEW YORK NY 10001 212-810-5300 BlackRock Inc. (Filed by) CIK : 0001364742 (see all company filings) EIN. : 320174431 | State of Incorp.: DE | Fiscal Year End: 1231 Type: SC 13G/A SIC : 6211 Security Brokers, Dealers & Flotation Companies (CF Office: 02 Finance)

View on Read The Filing